Kuwait Approves Emergency Use Of Oxford Covid-19 Vaccine

The Kuwaiti Ministry of Health announced the issuance of an emergency use license for the “Oxford” anti-corona virus vaccine that is manufactured in a serum factory in India with a license from the international company (AstraZeneca).

The Assistant Undersecretary for Drug and Food Control Affairs at the Ministry of Health, Dr. Abdullah Al-Badr, said in a press statement today, Friday, that this comes according to the decision of the joint technical committee between the Department of Registration and Control of Medicinal and Botanical Medicines and the Public Health Department for the evaluation and registration of vaccines and vaccines.

Al-Badr stated that the ministry had succeeded in obtaining an initial batch of the “Oxford” vaccine, due to its keenness not to delay the vaccination program, pointing out that the first batch is expected to arrive in days.

He explained that this vaccine has obtained approval from the European Medicines Authority and the British Agency for the Regulation of Medicines and Health Products, and the Serum Factory is a factory approved by the World Health Organization for the manufacture of vaccines and also from the Health Council of the Cooperation Council States 

He stressed that this decision came after an extensive review by the technical committee of all scientific data and reports, as the committee conducted a comprehensive assessment of safety, efficacy and quality information and also reviewed the results of clinical studies concerned with the effectiveness and safety of the vaccine.

He stated that the committee verified the quality reports and made sure that the principles of good manufacturing were applied in the factories producing the vaccine in accordance with international standards to ensure quality in all stages of manufacturing.

He indicated that the review process also included all technical and scientific aspects, stressing that the Ministry will carefully monitor the safety and safety of the vaccine after its use, in addition to continuing to follow up information and data about the safety, effectiveness and quality of the vaccine locally and internationally and take the necessary measures to ensure the safety of citizens and residents.

 

SOURCE KUWAITOFFERINGS

Comments Post Comment

Leave a Comment

Submit